Journal of Reproductive Health and Contraception

Abstract

The occurrence of vasogenic erectile dysfunction is strongly correlated to cardiovascular diseases (CVD). PDE5 inhibitors are currently first-line therapy. However, combined use with nitroglycerine, a key therapy in acute coronary syndrome, is contraindicated. The clinical prevalence of CVD with secondary erectile dysfunction necessitate research for alternative therapies.
Purpose: The purpose of this research was to compare the safety and efficacy of current first-line therapy to novel therapy LiESWT in the treatment of vasculogenic erectile dysfunction.
Materials and Methods: Research was conducted using the following: Ovid, PubMed, and Google Scholar. Keywords searched were “Erectile dysfunction”, “Extracorporeal shockwave therapy”, “Erectile function”, “IIEF”, and “Phosphodiesterase 5”. The inclusion criteria included men receiving treatment for ED and excluded meta-analyses or systematic review study designs. Twenty articles met the inclusion criteria. Population groups mainly consisted of men with ED